# Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

> **NCT04355806** · — · UNKNOWN · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 160 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Influenza Vaccine

## Interventions

- **DRUG:** PD-1/PD-L1 inhibitors
- **BIOLOGICAL:** Inactivated trivalent influenza vaccine

## Key facts

- **NCT ID:** NCT04355806
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2020-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04355806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04355806, "Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04355806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*